Literature DB >> 19523180

Health technology assessment in Canada: 20 years strong?

Devidas Menon1, Tania Stafinski.   

Abstract

Mesh：

Year:  2009        PMID： 19523180     DOI： 10.1111/j.1524-4733.2009.00554.x

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  12 in total

1.  Cost-effectiveness of chronic kidney disease mass screening test in Japan.

Authors:  Masahide Kondo; Kunihiro Yamagata; Shu-ling Hoshi; Chie Saito; Koichi Asahi; Toshiki Moriyama; Kazuhiko Tsuruya; Hideaki Yoshida; Kunitoshi Iseki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2011-12-14       Impact factor: 2.801

2.  The role of surgeons in identifying emerging technologies for health technology assessment.

Authors:  Tania Stafinski; Leigh-Ann Topfer; Ken Zakariasen; Devidas Menon
Journal:  Can J Surg       Date:  2010-04       Impact factor: 2.089

3.  Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study.

Authors:  Nicola Allen; Stuart R Walker; Lawrence Liberti; Chander Sehgal; M Sam Salek
Journal:  CMAJ Open       Date:  2016-11-03

4.  Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.

Authors:  Christian R C Kouakou; Thomas G Poder
Journal:  Eur J Health Econ       Date:  2021-08-21

5.  An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures.

Authors:  Léon Nshimyumukiza; Audrey Durand; Mathieu Gagnon; Xavier Douville; Suzanne Morin; Carmen Lindsay; Julie Duplantie; Christian Gagné; Sonia Jean; Yves Giguère; Sylvie Dodin; François Rousseau; Daniel Reinharz
Journal:  J Bone Miner Res       Date:  2013-02       Impact factor: 6.741

Review 6.  A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.

Authors:  Lianne Barnieh; Fiona Clement; Anthony Harris; Marja Blom; Cam Donaldson; Scott Klarenbach; Don Husereau; Diane Lorenzetti; Braden Manns
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

7.  Management of Medical Technology under the New Medical Policy Background in China.

Authors:  Suo-Wei Wu; Tong Chen; Ming Wu; Qi Pan; Yong Xuan; Liang-Yu Wei; Qin Wang; Chao Li; Jing-Chen Song
Journal:  Chin Med J (Engl)       Date:  2016-11-20       Impact factor: 2.628

8.  Establishment of a Quantitative Medical Technology Evaluation System and Indicators within Medical Institutions.

Authors:  Suo-Wei Wu; Tong Chen; Qi Pan; Liang-Yu Wei; Qin Wang; Chao Li; Jing-Chen Song; Ji Luo
Journal:  Chin Med J (Engl)       Date:  2018-06-05       Impact factor: 2.628

Review 9.  Priority-setting, the Indian way.

Authors:  Neethi V Rao; Laura Downey; Nishant Jain; Rama Baru; Francoise Cluzeau
Journal:  J Glob Health       Date:  2018-12       Impact factor: 4.413

10.  Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model.

Authors:  Léon Nshimyumukiza; Julie Duplantie; Mathieu Gagnon; Xavier Douville; Diane Fournier; Carmen Lindsay; Marc Parent; Alain Milot; Yves Giguère; Christian Gagné; François Rousseau; Daniel Reinharz
Journal:  Thromb J       Date:  2013-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.